This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Brain Biomarkers Market

Brain Biomarkers Market By Product Type, Application & Region - Forecast 2022 - 2032

Market Insights on Brain Biomarkers covering sales outlook, demand forecast & up-to-date key trends

Brain Biomarkers Market Snapshot

The global brain biomarkers market is anticipated to exhibit growth at a CAGR of 14.3% in the forecast period from 2022 to 2032. It is set to reach US$ 8.3 Billion in 2022 and US$ 11.5 Billion in 2032. The rising prevalence of various neurological diseases, such as brain tumors, migraines, epilepsy, and dementia is projected to drive the sales of brain biomarkers in future years.

Report Attribute

Details

Brain Biomarkers Market Estimated Base Year Value (2021)

US$ 7.1 Billion

Brain Biomarkers Market Expected Market Value (2022)

US$ 8.3 Billion

Brain Biomarkers Market Anticipated Forecast Value (2032)

US$ 11.5 Billion

Brain Biomarkers Market Projected Growth Rate (2022-2032)

14.3% CAGR

Biomarkers are referred to as molecules that indicate the presence of a dysfunction or disease. These are becoming increasingly important for monitoring disease progression, selecting the best treatments, and confirming diagnoses.

Neurological biomarkers are mainly present in Cerebrospinal Fluid (CSF) and rarely in blood. These can be studied by using CSF, but require an invasive lumbar puncture procedure.

Biomarker signatures are considered to be another powerful tool for studying neurological conditions and diseases. These are detected with the help of panels of high-quality antibodies.

The development of genomic biomarkers is projected to create new opportunities for the introduction of diagnostics that are based on a person’s specific genetic variations. Genomic biomarkers are also expected to help in the creation of personalized medicines.

Which are Some Major Factors Spurring Growth of the Brain Biomarkers Market

The ongoing technological advancement in the field of biomarkers and the emergence of biomarker signatures are expected to make neurological diseases more treatable. This is further expected to result in the early diagnosis, faster drug development, and non-invasive testing.

The launch of digital biomarkers by key players is set to deliver numerous pharmaceutical companies supplemental and contextual information to conclude clinical trials efficiently. Besides, government funding to accelerate research and development activities in various countries is expected to propel the demand for brain biomarkers in the assessment period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which Factors May Restrain the Brain Biomarkers Market Growth

The usage of brain biomarkers is limited to researchers for better understanding the disease progression. Several pharmaceutical and pathology companies worldwide are also using these to rapidly develop new therapeutics for neurodegenerative disorders. The lack of availability of commercial or direct-to-consumer tests may hamper the brain biomarkers market size in the near future.

Why is North America Projected to Dominate the Brain Biomarkers Market

North America is anticipated to lead in terms of the brain biomarkers market share during the forthcoming years. This growth is attributable to the rising research funding by regulatory bodies and the surging acceptance of biomarkers for drug development purposes in the U.S. and Canada.

The increasing prevalence of various neurological diseases across these developed countries is another significant factor that is estimated to augur well for the market.

As per the Centers for Disease Control and Prevention (CDC), at present, nearly 5.8 million people have Alzheimer’s disease in the U.S. Cases of Alzheimer’s disease are expected to reach 14 million by 2060 in the country. These numbers are projected to grow at a fast pace, thereby propelling the North America market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How is the Asia Pacific Brain Biomarkers Market Progressing

Asia Pacific is likely to exhibit a CAGR of 15.4% in the forecast period from 2022 to 2032. The rising number of clinical trials that are being conducted in China, Japan, India, and South Korea is projected to drive the Asia Pacific brain biomarkers market growth in future years.

The surging demand for targeted drugs to treat conditions associated with the central nervous system is another vital factor that is anticipated to augment the growth in the regional market. According to the National Health Portal, in India, the prevalence of dementia is set to be around 2.7%. This condition poses a great challenge in the country owing to the surging geriatric population. This factor is also expected to fuel the regional market.

Market Competition

Majority of the key players operating in the global market are striving to incorporate the latest technologies to make it easier for researchers to track the condition of the brain by measuring its molecules. They are consistently developing innovative brain testing methods to provide new treatment options and enable faster diagnosis. Meanwhile, a few other key players are aiming to invest huge sums in clinical trials to boost new product development.

Some of the leading companies present in the global brain biomarkers market include Siemens Healthineers, Electrical Geodesics, Lifesign LLC, Advanced Brain Monitoring, BrainScope, GE Healthcare, Johnson & Johnson, Natus Medical, F. Hoffmann-La Roche Ltd., Qiagen N.V., Nexus-DX, and NeuroVista among others.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 14.3% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Product Type
  • Disease Indication
  • Application
  • End User
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Siemens Healthineers
  • Electrical Geodesics
  • Lifesign LLC
  • Advanced Brain Monitoring
  • BrainScope
  • GE Healthcare
  • Johnson & Johnson
  • Natus Medical
  • F. Hoffmann-La Roche Ltd.
  • Qiagen N.V.
  • Nexus-DX
  • NeuroVista

Customization

Available Upon Request

Key Segments Profiled in the Brain Biomarkers Industry Survey

By Product Type:

  • Biomarker Test Kits
  • Biomarker Analyzers

By Disease Indication:

  • Stroke
  • MND & ALS
  • Alzheimer’s Disease & Other Dementias
  • Parkinson’s Disease
  • Huntington’s Disease

By Application:

  • Diagnosis
  • Drug Discovery and Development
  • Others

By End User:

  • Hospitals
  • Research Laboratories
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Frequently Asked Questions

The global brain biomarkers market is anticipated to surpass US$ 11.5 Billion in 2032.

North America is set to lead the brain biomarkers market in the forecast period.

Siemens Healthineers, Electrical Geodesics, Lifesign LLC, Advanced Brain Monitoring, BrainScope, GE Healthcare, and Johnson & Johnson are some of the renowned companies in the brain biomarkers market.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Wireless Brain Sensors Market

Published : March 2017

Healthcare

Prognostic Biomarkers Market

Published : March 2017

Healthcare

Molecular Biomarkers For Cancer Detection Market

Published : September 2016

Healthcare

Deep Brain Stimulator Market

Published : March 2016

Google translate

Brain Biomarkers Market